Celldex Therapeutics (NASDAQ:CLDX – Get Free Report) and Bicycle Therapeutics (NASDAQ:BCYC – Get Free Report) are both healthcare companies, but which is the better investment? We will contrast the two businesses based on the strength of their institutional ownership, profitability, earnings, valuation, risk, dividends and analyst recommendations.
Valuation and Earnings
This table compares Celldex Therapeutics and Bicycle Therapeutics”s revenue, earnings per share and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Celldex Therapeutics | $158,000.00 | 18,737.85 | -$258.76 million | ($4.35) | -8.67 |
| Bicycle Therapeutics | $72.86 million | 3.51 | -$218.96 million | ($2.73) | -1.34 |
Insider & Institutional Ownership
86.2% of Bicycle Therapeutics shares are owned by institutional investors. 5.2% of Celldex Therapeutics shares are owned by insiders. Comparatively, 22.0% of Bicycle Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.
Risk & Volatility
Celldex Therapeutics has a beta of 0.84, meaning that its stock price is 16% less volatile than the S&P 500. Comparatively, Bicycle Therapeutics has a beta of 1.54, meaning that its stock price is 54% more volatile than the S&P 500.
Profitability
This table compares Celldex Therapeutics and Bicycle Therapeutics’ net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| Celldex Therapeutics | N/A | -52.35% | -47.61% |
| Bicycle Therapeutics | -311.11% | -33.22% | -27.79% |
Analyst Recommendations
This is a breakdown of recent ratings and recommmendations for Celldex Therapeutics and Bicycle Therapeutics, as provided by MarketBeat.com.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Celldex Therapeutics | 1 | 1 | 10 | 1 | 2.85 |
| Bicycle Therapeutics | 1 | 3 | 5 | 0 | 2.44 |
Celldex Therapeutics presently has a consensus target price of $56.42, indicating a potential upside of 49.65%. Bicycle Therapeutics has a consensus target price of $13.86, indicating a potential upside of 279.13%. Given Bicycle Therapeutics’ higher possible upside, analysts plainly believe Bicycle Therapeutics is more favorable than Celldex Therapeutics.
Summary
Bicycle Therapeutics beats Celldex Therapeutics on 10 of the 15 factors compared between the two stocks.
About Celldex Therapeutics
Celldex Therapeutics, Inc., a biopharmaceutical company, engages in developing therapeutic monoclonal and bispecific antibodies for the treatment of various diseases. Its drug candidates include antibody-based therapeutics to treat patients with inflammatory, allergic, autoimmune, and other devastating diseases. The company’s clinical development programs CDX-0159, a Phase II monoclonal antibody that binds the receptor tyrosine kinase KIT and inhibits its activity. It has research collaboration and license agreements with Yale University. The company was incorporated in 1983 and is headquartered in Hampton, New Jersey.
About Bicycle Therapeutics
Bicycle Therapeutics plc, a clinical-stage biopharmaceutical company, develops a class of medicines for diseases that are underserved by existing therapeutics in the United States and the United Kingdom. Its product pipeline comprising BT8009, a bicycle toxin conjugate (BTC) which is in phase I/II/III clinical trial for the treatment of high nectin-4 expressing tumors; BT5528, a BTC which is in phase I/II clinical trial for the treatment of Ephrin type A receptor 2 expressing tumor; BT7480, a Bicycle TICA molecule which is in phase I/II targeting Nectin-4 and agonizing CD137; and BT7455, a Bicycle TICA molecule targeting Ephrin type A receptor 2 and CD137 and is in preclinical trial. The company also developing BT1718, a bicycle toxin conjugate (BTC), which is in Phase I/IIa clinical trials targeting tumors that express Membrane Type 1 matrix metalloprotease; and BT7401, a multivalent bicycle CD137 agonist which is in phase IIa to treat advanced solid tumors. In addition, it develops Novel anti-infective, which is in preclinical trial targeting anti-infectives disease; CNS targets, which is in preclinical trial targeting CNS disease; and Novel neuromuscular targets, which is in preclinical trial targeting neuromuscular disease. Further, the company collaborates with biopharmaceutical companies and organizations to develop programs in therapeutic areas. It has collaboration and license agreement with Bayer Consumer Care AG; Novartis Pharma AG; Cancer Research UK; Cancer Research Technology Ltd; and Oxurion NV. Bicycle Therapeutics plc was incorporated in 2009 and is headquartered in Cambridge, the United Kingdom.
Receive News & Ratings for Celldex Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Celldex Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
